Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

GLP-1 weight-loss drugs alleviate obesity as well as provide other health benefits. Yet they are also the focus of ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Sen. Bernie Sanders questions Novo Nordisk CEO Lars Jorgensen in a hearing on Capitol Hill about the high prices Americans pay for Ozempic and Wegovy compared with people in other countries.

What I am asking you is, if you don’t act, 40,000 people a year could die? Is this acceptable to you?” the senator asked.

Large employers could spend as much as an additional 7.8% in health costs next year, according to a Business Group on Health survey.

Obesity is high and holding steady in the U.S., but the proportion of those with severe obesity has climbed since a decade ...

(ABC 6 News) — On Tuesday, lawmakers grilled the CEO of the company that makes Ozempic and Wegovy over the price tag of those ...

The CEO of Novo Nordisk took questions for more than two hours during a Senate Health Committee hearing focused on addressing ...

For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised ...